Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
Due to the ongoing local COVID-19 outbreaks in various areas across England, the Secretary of State for Health and Social Care has decided that the pandemic delivery service requirements should continue to apply from 24th September 2020 until 5th October 2020, but only for shielded patients who live in the following local outbreak areas: 8 wards...
Update (23/09/2020) resupply date now Q1 2021 The manufacturer Marlborough Pharmaceuticals has advised that Cloral betaine 707mg tablets are out of stock with resupply expected November 2020. In the interim, supply of an alternative imported unlicensed medicinal product (specials) is available through Alliance Healthcare Specials using PIP code: 802-0745. A prescription for a pack of...
Interoperability between IT systems is something modern consumers now demand in their day to day lives and pharmacy team members are no different, with integration between different pharmacy systems being a highly desired feature identified in responses to surveys undertaken by the Community Pharmacy IT Group (CP ITG). Pharmacy IT suppliers have been developing their...
NHS England and NHS Improvement (NHSE&I) have today published guidance on the Part 2 Pharmacy Quality Scheme (PQS) 2020/21. This guidance builds on the information on the PQS contained within the September Drug Tariff. All pharmacy contractors who are planning to participate in and make a claim for the PQS are advised to read the...
The Drug Tariff Category M pricelist for October 2020 has been published on the NHS BSA website. Adjustments have been made which incorporate a reduction in the uplift previously applied from June 2020, along with an increase to margin run rates, and increases to reflect increased medicine buying costs. PSNC analysis indicates that the overall...
Further to our news article on 6th August 2020 highlighting the initial information on the Part 2 PQS for 2020/21, contractors were advised to leave the completion of the e-learning associated with the Infection Prevention and Control criteria until late September. This was to allow NHS England and NHS Improvement (NHSE&I) to adapt the training...
Pharmacy contractors and their teams will be aware from national media reports of the increasing numbers of COVID-19 infections and the actions being taken by the Governments across the UK to tackle local outbreaks. This morning at a Government press briefing, Professor Chris Whitty, Chief Medical Officer and Sir Patrick Vallance, Chief Scientific Adviser, highlighted...
Last month the Department of Health and Social Care (DHSC) announced that community pharmacies could now order additional personal protective equipment (PPE) through the online portal in an emergency. By now, community pharmacies should have received an email invitation to their shared NHSmail inbox to register to access the portal. If they have not responded...
New NHS guidance for Primary Care Networks (PCNs) on the provision of Structured Medication Reviews (SMR) includes referrals being made to the community pharmacy New Medicine Service. The guidance has been published by NHS England and NHS Improvement to support PCN clinical pharmacy teams with implementation of the structured medication review and optimisation service requirements...
Each year, pharmacies are required to participate in up to six public health campaigns at the request of NHS England and NHS Improvement (NHSE&I). The topics of these campaigns are agreed by NHSE&I and PSNC. At the start of 2020/21 we agreed that the campaigns would be suspended due to the COVID-19 pandemic. We have...
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
New recommendations following a review of the risks of dependence and addiction associated with prolonged use of opioid medicines (opioids) for non-cancer pain. Before prescribing opioids, discuss with the patient the risks and features of tolerance, dependence, and addiction, and agree together a treatment strategy and plan for end of treatment.
Following a review of the risks associated with use of opioid medicines for non-cancer pain, the Commission on Human Medicines (CHM) has recommended that fentanyl transdermal patches are contraindicated in opioid-naive patients in the UK.
In autoimmune conditions and some cancer therapies, methotrexate should be taken once a week; however, we continue to receive reports of inadvertent overdose due to more frequent dosing (including daily administration). New measures have been implemented to prompt healthcare professionals to record the day of the week for intake and to remind patients of the dosing schedule and the risks of overdose.
Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region.
A summary of letters and drug alerts recently sent to healthcare professionals.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
Advice for investigators and sponsors of ongoing clinical investigations.
The different types of tests and testing kits for COVID-19, and the specifications for manufacturers.
List of manufacturers and their medical devices which have been granted an exemption by the MHRA. The list also includes manufacturers whose exemption expired or was cancelled. This information will be listed for 2 months after expiry or cancellation.
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
List of Field Safety Notices (FSNs) from medical device manufacturers from 14 September to 18 September 2020
Department of Health and MHRA register of licensed manufacturing sites - manufacturer specials (human) (MS) and manufacturer specials authorisation (veterinary) (MANSA) only.
The MHRA will now issue all safety-critical alerts for medicines and medical devices that require action as National Patient Safety Alerts
EAMS scientific opinion issued to Merck Serono Limited for avelumab in the treatment of adults with bladder cancer that has spread beyond the bladder (advanced urothelial carcinoma) if the cancer did not get worse after chemotherapy.
EAMS scientific opinion issued to Roche Products Limited for Risdiplam 0.75 mg/ml powder for oral solution in the treatment of type 1 and type 2 Spinal Muscular Atrophy (SMA) in patients 2 months and older who are not suitable for authorised treatments.
Reporting suspected side effects or incidents to the Yellow Card scheme supports the safe use of medical products for everyone
You must get permission to export certain drugs and medicines.
Medicines from the listed parallel distributors are being recalled due to concerns that the supply chain may have been compromised and the origins of the products are unknown
Summary list of field safety notices (FSNs) from medical device manufacturers from 7 to 11 September 2020.
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
Guidance for the pharmaceutical industry on location and other authorised personnel requirements post transition period.
You must get permission to export certain drugs and medicines.
Product defect recall alert for Prednidale 5 mg Tablets (Vm 10434/4009) by Dechra Ltd
This is the hub for all the Veterinary Medicines Directorate's communications on the changes following the end of the Transition Period.
Service for Marketing Authorisation Holders and their associated businesses, to license veterinary medicines in the UK and report any problems with their use.
Guidance for the veterinary pharmaceutical industry on the implementation of the Northern Ireland Protocol. This guidance will be updated with more information as it becomes available.
Guidance for the pharmaceutical industry on how to apply for and manage an authorisation to place a veterinary medicine on the UK market post transition period. This guidance will be updated with more information as it becomes available.
Guidance for the pharmaceutical industry on importing and exporting veterinary medicines post transition period.
Web services, such as the Special Imports System and Adverse Event Reporting will be unavailable due to essential maintenance.
Reporting against VMD published standards up to 31 March 2020.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
News and guidance on veterinary medicines issues affected by coronavirus (COVID-19).
Product defect recall alert for Johnson’s 4Fleas 80mg Spot-on Solution for Cats (Vm 00010/4181), by Johnson’s Veterinary Products Ltd.
VMD will re-start on-site inspections of manufacturers, wholesalers, vet practices, feed business operators and SQP retailer premises.
Details of 24 FOI requests received by the VMD in the first six months of 2020
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Web services, such as the Special Imports System and Adverse Event Reporting will be unavailable due to essential electrical maintenance.
Report of the ten products for which most Special Import Certificates (SIC) have been issued by VMD in the UK.
The Leeds Dementia Pathfinder project supported patients and carers with tech devices
Study detected Nonalcoholic Fatty Liver Disease and Nonalcoholic steatohepatitis
European Medicines Agency grants designation based on phase I/II data
Upfront funding will be used to scale-up manufacturing
Data presented at 2020 ESMO virtual congress
Swiss pharma company to acquire biotech for $449m (€380m)
Both PARP inhibitors receive positive opinions from CHMP
Decision made following review of rising COVID-19 cases
Data shows a range of responses in different tumours
Investors include SV Health Investors and Cancer Research UK
Detailed results presented at ESMO also show benefit in prostate cancer
Positive opinions include Pacira's Exparel and two new vaccines from Sanofi
The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC
Tumour agnostic therapy demonstrates sustained efficacy
Concerns over NHS Test and Trace system exacerbated by continuing rise in cases
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available